The clinical effects of purslane (Portulaca oleracea) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver diseases associated with unfavorable metabolic profiles and oxidative stress parameters. This study was designed to determine the effects of purslane seeds consumption with a low‐calorie diet on insulin resistance, lipid profile, and oxidative stress indices in patients with NAFLD. This randomized controlled clinical trial was conducted on 54 individuals with NAFLD. Subjects were randomly assigned to consume either 10 g/day of purslane seeds sachet before breakfast and dinner in addition to a low‐calorie diet (n = 27) or only the low‐calorie diet (n = 27) for 8 weeks. Fasting blood samples were collected at the beginning and end of the study to measure relevant variables. Intake of purslane seeds with the low‐calorie diet led to a significant decrease in serum concentrations of fasting blood sugar (FBS; −3.52 ± 10.45 compared with 3.03 ± 9.01 mg/dl, P = 0.017), quantitative insulin sensitivity check index (QUICKI; 0.13 ± 0.27 compared with −0.002 ± 0.016, P = 0.017), total cholesterol (4.33 ± 34.04 compared with 23.48 ± 29.47 mg/dl, P = 0.032), and low‐density lipoprotein cholesterol (LDL‐C; −4.35 ± 22.65 compared with 11.82 ± 16.08 mg/dl, P = 0.004) after intervention. Compared with the control group, purslane seeds consumption with adherence to a low‐calorie diet had beneficial effects on FBS, HOMA‐IR, QUICKI, serum total, and LDL‐C in patients with NAFLD but did not affect other glycemic, lipid profile, and oxidative stress parameters.

Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double‐blind clinical trial

“…To our knowledge, this study is the first randomized, double-blind clinical trial, which has assessed the effects of purslane extract on NAFLD characteristics. In fact, previous clinical trials assessing the effects of purslane, have focused on the effects of purslane seeds rather than purslane extract (Dehghan et al, 2016;El-Sayed, 2011;Esmaillzadeh et al, 2015;Gheflati et al, 2019). Our results demonstrated that 300 mg/day of purslane extract supplementation, had no effect on lipid profile, glycemic indices and liver enzymes.…”

“…Then, a balanced diet, providing about 500 kcal/day less than the total daily energy requirement (15% protein, 55% carbohydrate, and 30% fat), was calculated and prescribed for each patient. The percentage of macronutrients was in accordance with the recommendations for NAFLD (Gheflati, Adelnia, & Nadjarzadeh, 2019;Jeznach-Steinhagen et al, 2019). The minimum calculated energy for weight reduction was about 1,300 kcal.…”

“…Wainstein et al found that daily consumption of 180 mg of purslane extract for 12 weeks had no effect on glycemic status, including FBG, insulin levels and HOMA-IR in patients with type 2 diabetes (Wainstein et al, 2016). Other studies have reported favorable effects of purslane seed consumption on FBG (Adelnia Najafabadi, Dehghani, Behradmanesh, & Najarzadeh, 2015;Dehghan et al, 2016;El-Sayed, 2011;Gheflati et al, 2019;Papoli, Pishdad, Nadjarzadeh, & Hosseinzadeh, 2019), fasting insulin (El-Sayed, 2011) and insulin resistance or sensitivity (Gheflati et al, 2019). However, no significant changes in FBG (Esmaillzadeh et al, 2015;Wainstein et al, 2016), insulin level (Esmaillzadeh et al, 2015;Gheflati et al, 2019;Wainstein et al, 2016) and HOMA-IR (Esmaillzadeh et al, 2015;Wainstein et al, 2016) have been reported by some studies.…”

The Effect of a Persian Herbal Medicine Compound on the Lipid Profiles of Patients with Dyslipidemia: A Randomized Double-Blind Placebo-Controlled Clinical Trial

“…Using Stata software, considering alpha 5%, power 90%, and based on Gheflati et al [ 39 ] studying that the mean of LDL was 120.8 standard deviation (SD = 24.8) in the intervention group (purslane seeds) and 148.4 (SD = 35.8) in the control group, the required sample size in each group was estimated to be 27 cases; considering the probability of attrition, 37 cases were calculated for each group. By expanding this sample size to the number of groups, 74 cases were entered into the study.…”

Study on the Independent Effect of Thyroid Hormone Based on Uric Acid Level on NAFLD

“…Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease characterized by the accumulation of fat in the liver, which can be associated with obesity, and can progress to brosis, cirrhosis, and even liver cancer [1].NAFLD is considered as an important feature of metabolic syndrome and an important factor causing cardiovascular diseases. More studies have suggested that NAFLD is related to male sexual dysfunction and reproductive dysfunction [2].NAFLD has also been shown to be associated with poor metabolism and oxidative stress [3].Other studies have linked NAFLD to sedentary behavior and poor eating habits [4].NAFLD is one of the most common chronic liver diseases in developed countries [5]. Except for lifestyle intervention, no drugs are currently approved for the treatment of NAFLD, so more clinical studies are needed to nd new methods for the treatment and management of NAFLD.…”